The antimetabolite 3-bromopyruvate selectively inhibits Staphylococcus aureus.

@article{Visca2019TheA3,
  title={The antimetabolite 3-bromopyruvate selectively inhibits Staphylococcus aureus.},
  author={Paolo Visca and Federica Edith Pisa and Francesco 6 Imperi},
  journal={International journal of antimicrobial agents},
  year={2019},
  volume={53 4},
  pages={
          449-455
        }
}
Increased antibacterial resistance jeopardizes current therapeutic strategies to control infections, soliciting the development of novel antibacterial drugs with new mechanisms of action. This study reports the discovery of potent and selective antistaphylococcal activity of 3-bromopyruvate (3BP), an antimetabolite in preclinical development as an anticancer drug. 3BP showed bactericidal activity against Staphylococcus aureus, with active concentrations comparable with those reported to be… CONTINUE READING
BETA